GATA3 Antibody
- Known as:
- GATA3 Antibody
- Catalog number:
- Y212708
- Product Quantity:
- 200ul
- Category:
- -
- Supplier:
- ABM
- Gene target:
- GATA3 Antibody
Related genes to: GATA3 Antibody
- Gene:
- GATA3 NIH gene
- Name:
- GATA binding protein 3
- Previous symbol:
- -
- Synonyms:
- HDR
- Chromosome:
- 10p14
- Locus Type:
- gene with protein product
- Date approved:
- 1992-11-03
- Date modifiied:
- 2016-10-05
Related products to: GATA3 Antibody
Related articles to: GATA3 Antibody
- The prevalence of food allergy has been rising over the past decade, but effective treatments remain limited. The purpose of this study was to investigate the effect of ginkgolide B (GB), a natural bioactive compound with well-documented anti-inflammatory and immunoregulatory properties, on a mouse model of food allergy and to elucidate the mechanism mediated by the mTOR signaling pathway. - Source: PubMed
Publication date: 2026/08/18
Zhou RongqinYang XiaotongTan PanpanWang HuanZeng DanMa Xiaojuan - Asthma is a chronic inflammatory airway disease characterized by Th2- dominant immune responses, airway hyperresponsiveness, and structural remodeling. Although inhaled corticosteroids and biologics are effective for many patients, a substantial proportion remains poorly controlled and experiences treatment-related adverse effects. Probiotics have emerged as immunomodulatory agents in asthma, but existing studies predominantly focus on oral administration and gut-lung axis regulation. Whether direct respiratory administration of probiotics can modulate the pulmonary immune microenvironment and alleviate asthma remains largely unexplored. - Source: PubMed
Publication date: 2026/09/01
Yang XinYu FanWu XiaochengLi ShuxianWang YingshuoHu ZhongXie YichengMa DaqingWu Lei - Loss of estrogen receptor (ER) and/or progesterone receptor (PR) might occur during the metastatic progression of ER positive and HER2 negative (ER+/HER2-) breast cancer (BC), but the underpinning molecular alterations remain elusive. We explored the genomic context of HER2- tumors with ER and/or PR loss to investigate potential drivers and actionable alterations that might help personalize treatment of ER+/HER2- BC. - Source: PubMed
Publication date: 2026/08/10
Migliaccio IleniaPaoli MartaBiagioni ChiaraGuarducci CristinaGalardi FrancescaAnichini GiuliaBiganzoli LauraBenelli MatteoMalorni Luca - Background, aim, and objectives: Accurate diagnosis of urothelial carcinoma (UC), particularly in high-grade and limited biopsy specimens, may be challenging on morphology alone. Immunohistochemistry (IHC) markers such as GATA3, uroplakin II (UPII), and p40 may improve diagnostic confidence. This study aimed to evaluate the diagnostic utility of GATA3, UPII, and p40, individually and as a combined panel, in urothelial carcinoma, and to correlate marker expression with tumor grade and invasion status. - Source: PubMed
Publication date: 2026/07/31
Manjari LavanyaM R AmruthaK R RameshP O VivekH Shruthi - Paragangliomas (PGLs) are rare neuroendocrine tumors arising from extra-adrenal chromaffin cells, with head and neck paragangliomas (HNPGLs) accounting for only a small proportion of all cases. Although most HNPGLs are benign, slow-growing, and nonfunctional, a minority develop metastatic disease, for which reliable histopathologic predictors remain lacking. We report the case of a 63-year-old man who presented with a progressively enlarging left-sided neck mass that had been present for more than 30 years before evaluation. Imaging demonstrated a carotid body paraganglioma with cervical lymph node involvement and distant suspected metastases to the thoracic and lumbar spine, lung, salivary gland, shoulder soft tissue, and small bowel. Histopathology confirmed paraganglioma with classic Zellballen architecture and positive staining for synaptophysin, chromogranin-A, CD56, GATA3, and S100-positive sustentacular cells. Given the patient's minimal symptoms despite extensive metastatic disease, a multidisciplinary team initially pursued active surveillance with serial multimodal imaging. Radiographic progression over time prompted initiation of systemic therapy with cabozantinib, which resulted in decreased metabolic activity of the primary tumor and no fluorodeoxyglucose-avid evidence of metastatic disease on follow-up imaging. This case highlights the unpredictable biological behavior of carotid body paragangliomas, demonstrating that longstanding, minimally symptomatic tumors may ultimately progress to widespread metastatic disease. It further emphasizes the importance of prolonged surveillance, multimodal imaging, multidisciplinary management, and individualized treatment strategies for patients with metastatic HNPGLs in the absence of reliable predictors of malignant potential. - Source: PubMed
Publication date: 2026/08/28
Parkhurst Erik LHamad Amar